Anti‐platelet therapy: cyclo‐oxygenase inhibition and the use of aspirin with particular regard to dual anti‐platelet therapy
Open accessThe DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Abstract
Aspirin and P2Y 12 antagonists are commonly used anti‐platelet agents. Aspirin produces its effects through inhibition of thromboxane A 2(TXA 2) production, while P2Y 12 antagonists attenuate the secondary responses to ADP released by activated platelets. The anti‐platelet effects of aspirin and a P2Y 12 antagonist are often considered to be separately additive. However, there is evidence of an overlap in effects, in that a high level of P2Y 12 receptor inhibition can blunt TXA 2 receptor signalling in platelets and reduce platelet production of TXA 2. Against this background, the addition of aspirin, particularly at higher doses, could cause significant reductions in the production of prostanoids in other tissues, e.g. prostaglandin I 2 from the blood vessel wall. This review summarizes the data from clinical studies in which dose‐dependent effects of aspirin on prostanoid production have been evaluated by both plasma and urinary measures. It also addresses the biology underlying the cardiovascular effects of aspirin and its influences upon prostanoid production throughout the body. The review then considers whether, in the presence of newer, more refined P2Y 12 receptor antagonists, aspirin may offer less benefit than might have been predicted from earlier clinical trials using more variable P2Y 12 antagonists. The possibility is reflected upon, that when combined with a high level of P2Y 12 blockade the net effect of higher doses of aspirin could be removal of anti‐thrombotic and vasodilating prostanoids and so a lessening of the anti‐thrombotic effectiveness of the treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Vane, J. R., Bakhle, Y. S., & Botting, R. M. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.97 · Cited by 2,734
Cyclooxygenase in biology and disease
DuBois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., van de Putte, L. B. A., & Lipsky, P. E. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.12.1063 · Cited by 2,506
Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs
Wolfe, M. M., Lichtenstein, D. R., & Singh, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906173402407 · Cited by 1,956
Kujubu, D. A., Fletcher, B. S., Varnum, B. C., Lim, R. W., & Herschman, H. R. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98774-0 · Cited by 1,789
Xie, W. L., Chipman, J. G., Robertson, D. L., Erikson, R. L., & Simmons, D. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.7.2692 · Cited by 1,707
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
Hla, T., & Neilson, K. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7384 · Cited by 1,465
Kearney, P. M., Baigent, C., Godwin, J., Halls, H., Emberson, J. R., & Patrono, C. (2006) · BMJ · doi:10.1136/bmj.332.7553.1302 · Cited by 1,445
McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
Low-Dose Aspirin for the Prevention of Atherothrombosis
Patrono, C., García Rodríguez, L. A., Landolfi, R., & Baigent, C. (2005) · New England Journal of Medicine · doi:10.1056/nejmra052717 · Cited by 1,218
Sugimoto, Y., & Narumiya, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.r600038200 · Cited by 1,196
Grosser, T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27291 · Cited by 1,027
Coxibs and Cardiovascular Disease
FitzGerald, G. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048288 · Cited by 899
Mehta, S. R., Tanguay, J.-F., Eikelboom, J. W., Jolly, S. S., Joyner, C. D., Granger, C. B., Faxon, D. P., Rupprecht, H.-J., Budaj, A., Avezum, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61088-4 · Cited by 825
cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase.
O'Banion, M. K., Winn, V. D., & Young, D. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.11.4888 · Cited by 821
Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., & Taubert, K. A. (2007) · Circulation · doi:10.1161/circulationaha.106.181424 · Cited by 804
Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2
Cheng, Y., Austin, S. C., Rocca, B., Koller, B. H., Coffman, T. M., Grosser, T., Lawson, J. A., & FitzGerald, G. A. (2002) · Science · doi:10.1126/science.1068711 · Cited by 789
Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909475 · Cited by 768
(1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251801 · Cited by 759
Patrono, C., Baigent, C., Hirsh, J., & Roth, G. (2008) · Chest · doi:10.1378/chest.08-0672 · Cited by 748
Peters, R. J. G., Mehta, S. R., Fox, K. A. A., Zhao, F., Lewis, B. S., Kopecky, S. L., Diaz, R., Commerford, P. J., Valentin, V., & Yusuf, S. (2003) · Circulation · doi:10.1161/01.cir.0000091201.39590.cb · Cited by 706
Mechanism of Action of Nonsteroidal Anti-inflammatory Drugs
Vane, J. R., & Botting, R. M. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00203-9 · Cited by 688
FitzGerald, G. A., Oates, J. A., Hawiger, J., Maas, R. L., Roberts, L. J., Lawson, J. A., & Brash, A. R. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110814 · Cited by 665
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic
Warner, T. D., & Mitchell, J. A. (2004) · The FASEB Journal · doi:10.1096/fj.03-0645rev · Cited by 614
Self-citationCatella-Lawson, F., McAdam, B., Morrison, B. W., Kapoor, S., Kujubu, D., Antes, L., Lasseter, K. C., Quan, H., Gertz, B. J., & Fitzgerald, G. A. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38195-9 · Cited by 597
Aging-Induced Phenotypic Changes and Oxidative Stress Impair Coronary Arteriolar Function
Csiszar, A., Ungvari, Z., Edwards, J. G., Kaminski, P., Wolin, M. S., Koller, A., & Kaley, G. (2002) · Circulation Research · doi:10.1161/01.res.0000020401.61826.ea · Cited by 563
Lanas, A., García-Rodríguez, L. A., Arroyo, M. T., Gomollón, F., Feu, F., González-Pérez, A., Zapata, E., Bástida, G., Rodrigo, L., Santolaria, S., et al. (2006) · Gut · doi:10.1136/gut.2005.080754 · Cited by 524
Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme
Masferrer, J. L., Seibert, K., Zweifel, B., & Needleman, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.3917 · Cited by 461
The development of COX2 inhibitors
Flower, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1034 · Cited by 459
Wiviott, S. D., Braunwald, E., McCabe, C. H., Horvath, I., Keltai, M., Herrman, J.-P. R., Van de Werf, F., Downey, W. E., Scirica, B. M., Murphy, S. A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60422-5 · Cited by 453
Weksler, B. B., Pett, S. B., Alonso, D., Richter, R. C., Stelzer, P., Subramanian, V., Tack-Goldman, K., & Gay, W. A. (1983) · New England Journal of Medicine · doi:10.1056/nejm198304073081402 · Cited by 448
Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review
Campbell, C. L., Smyth, S., Montalescot, G., & Steinhubl, S. R. (2007) · JAMA · doi:10.1001/jama.297.18.2018 · Cited by 444
Value and Limitations of Existing Scores for the Assessment of Cardiovascular Risk
Cooney, M. T., Dudina, A. L., & Graham, I. M. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.020 · Cited by 436
Reilly, I., & FitzGerald, G. (1987) · Blood · doi:10.1182/blood.v69.1.180.180 · Cited by 419
Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance
Cattaneo, M. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000145980.39477.a9 · Cited by 411
Hallas, J., Dall, M., Andries, A., Andersen, B. S., Aalykke, C., Hansen, J. M., Andersen, M., & Lassen, A. T. (2006) · BMJ · doi:10.1136/bmj.38947.697558.ae · Cited by 403
Inhibition of prostaglandin biosynthesis
Flower, R. J., & Vane, J. R. (1974) · Biochemical Pharmacology · doi:10.1016/0006-2952(74)90381-5 · Cited by 401
Synthesis of Prostacyclin from Platelet-derived Endoperoxides by Cultured Human Endothelial Cells
Marcus, A. J., Weksler, B. B., Jaffe, E. A., & Broekman, M. J. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109967 · Cited by 380
Augmented Expression of Cyclooxygenase-2 in Human Atherosclerotic Lesions
Schönbeck, U., Sukhova, G. K., Graber, P., Coulter, S., & Libby, P. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65230-3 · Cited by 379
Cyclooxygenase-1 and -2–Dependent Prostacyclin Formation in Patients With Atherosclerosis
Belton, O., Byrne, D., Kearney, D., Leahy, A., & Fitzgerald, D. J. (2000) · Circulation · doi:10.1161/01.cir.102.8.840 · Cited by 377
Kobayashi, T., Tahara, Y., Matsumoto, M., Iguchi, M., Sano, H., Murayama, T., Arai, H., Oida, H., Yurugi-Kobayashi, T., Yamashita, J. K., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421446 · Cited by 373
Patrono, C., Patrignani, P., & Rodríguez, L. A. G. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13418 · Cited by 364
Suppression of Thromboxane A2but Not of Systemic Prostacyclin by Controlled-Release Aspirin
Clarke, R. J., Mayo, G., Price, P., & FitzGerald, G. A. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110173251605 · Cited by 346
Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function
Cheng, Y. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27540 · Cited by 339
COX-2 Inhibitors and Cardiovascular Risk
Funk, C. D., & FitzGerald, G. A. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318157f72d · Cited by 330
Wiviott, S. D., Antman, E. M., Gibson, C. M., Montalescot, G., Riesmeyer, J., Weerakkody, G., Winters, K. J., Warmke, J. W., McCabe, C. H., & Braunwald, E. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.04.012 · Cited by 324
Rocca, B., Secchiero, P., Ciabattoni, G., Ranelletti, F. O., Catani, L., Guidotti, L., Melloni, E., Maggiano, N., Zauli, G., & Patrono, C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.112202999 · Cited by 317
P2 receptors, platelet function and pharmacological implications
Gachet, C. (2008) · Thrombosis and Haemostasis · doi:10.1160/th07-11-0673 · Cited by 297
Baker, C. S. R., Hall, R. J. C., Evans, T. J., Pomerance, A., Maclouf, J., Creminon, C., Yacoub, M. H., & Polak, J. M. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.3.646 · Cited by 296
REGULATION OF PLATELET FUNCTIONS BY P2 RECEPTORS
Gachet, C. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141207 · Cited by 295
11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation.
Catella, F., Healy, D., Lawson, J. A., & FitzGerald, G. A. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.16.5861 · Cited by 286
Mitchell, J. A., & Warner, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1929 · Cited by 279
Self-citationEstimated rate of prostacyclin secretion into the circulation of normal man.
FitzGerald, G. A., Brash, A. R., Falardeau, P., & Oates, J. A. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110373 · Cited by 269
Zidar, N., Odar, K., Glavac, D., Jerse, M., Zupanc, T., & Stajer, D. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00430.x · Cited by 255
Jakubowski, J. A., Winters, K. J., Naganuma, H., & Wallentin, L. (2007) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2007.00027.x · Cited by 250
Reticulated platelets and uninhibited COX‐1 and COX‐2 decrease the antiplatelet effects of aspirin
GUTHIKONDA, S., LEV, E. I., PATEL, R., DELAO, T., BERGERON, A. L., DONG, J. ‐., & KLEIMAN, N. S. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02387.x · Cited by 245
Estimated rate of thromboxane secretion into the circulation of normal humans.
Patrono, C., Ciabattoni, G., Pugliese, F., Pierucci, A., Blair, I. A., & FitzGerald, G. A. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112341 · Cited by 234
Nucleotide receptor signaling in platelets
KAHNER, B. N., SHANKAR, H., MURUGAPPAN, S., PRASAD, G. L., & KUNAPULI, S. P. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02192.x · Cited by 219
Praticò, D., Tillmann, C., Zhang, Z.-B., Li, H., & FitzGerald, G. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061607398 · Cited by 215
Tohgi, H., Konno, S., Tamura, K., Kimura, B., & Kawano, K. (1992) · Stroke · doi:10.1161/01.str.23.10.1400 · Cited by 208
Coronary Vasoconstrictor Effect of Indomethacin in Patients with Coronary-Artery Disease
Friedman, P. L., Brown, E. J., Gunther, S., Alexander, R. W., Barry, W. H., Mudge, G. H., & Grossman, W. (1981) · New England Journal of Medicine · doi:10.1056/nejm198111123052002 · Cited by 205
ARMSTRONG, P. C. J., LEADBEATER, P. D., CHAN, M. V., KIRKBY, N. S., JAKUBOWSKI, J. A., MITCHELL, J. A., & WARNER, T. D. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04160.x · Cited by 203
Self-citationDuffy, S. J., Castle, S. F., Harper, R. W., & Meredith, I. T. (1999) · Circulation · doi:10.1161/01.cir.100.19.1951 · Cited by 198
Xiao, C.-Y., Hara, A., Yuhki, K.-I., Fujino, T., Ma, H., Okada, Y., Takahata, O., Yamada, T., Murata, T., Narumiya, S., et al. (2001) · Circulation · doi:10.1161/hc4301.098058 · Cited by 197
Hanley, S. P., Cockbill, S. R., Bevan, J., & Heptinstall, S. (1981) · The Lancet · doi:10.1016/s0140-6736(81)91733-5 · Cited by 195
Egan, K. M., Wang, M., Lucitt, M. B., Zukas, A. M., Puré, E., Lawson, J. A., & FitzGerald, G. A. (2005) · Circulation · doi:10.1161/01.cir.0000153386.95356.78 · Cited by 193
Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications
Hernández-Díaz, S., & García Rodríguez, L. A. (2006) · BMC Medicine · doi:10.1186/1741-7015-4-22 · Cited by 186
Function of prostanoid receptors: studies on knockout mice
Kobayashi, T., & Narumiya, S. (2002) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(02)00055-2 · Cited by 185
Gross, S., Tilly, P., Hentsch, D., Vonesch, J.-L., & Fabre, J.-E. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061617 · Cited by 180
The enzymology of prostaglandin endoperoxide H synthases-1 and -2
Smith, W. L., & Song, I. (2002) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(02)00025-4 · Cited by 173
Warner, T. D., & Mitchell, J. A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60137-3 · Cited by 166
Self-citation&NA; (2002) · Journal of Hypertension · doi:10.1097/00004872-200212000-00001 · Cited by 160
Frequency of Analgesic Use and Risk of Hypertension Among Men
Forman, J. P. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.4.394 · Cited by 155
Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation
Rosen, G. D., Birkenmeier, T. M., Raz, A., et al. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)91819-6 · Cited by 152
Roy, P. K., Bonello, L., Torguson, R., de Labriolle, A., Lemesle, G., Slottow, T. L. P., Steinberg, D. H., Kaneshige, K., Xue, Z., Satler, L. F., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.07.063 · Cited by 137
Aspirin causes short-lived inhibition of bradykinin-stimulated prostacyclin production in man
Heavey, D. J., Barrow, S. E., Hickling, N. E., & Ritter, J. M. (1985) · Nature · doi:10.1038/318186a0 · Cited by 133
Cardiovascular Effects of the Cyclooxygenase Inhibitors
White, W. B. (2007) · Hypertension · doi:10.1161/01.hyp.0000258106.74139.25 · Cited by 128
Evangelista, V., Manarini, S., Santo, A. D., Capone, M. L., Ricciotti, E., Francesco, L. D., Tacconelli, S., Sacchetti, A., D’Angelo, S. P., Scilimati, A., et al. (2006) · Circulation Research · doi:10.1161/01.res.0000214553.37930.3e · Cited by 127
Arehart, E. J., Stitham, J., Asselbergs, F. W., Douville, K. L., MacKenzie, T. A., Fetalvero, K. M., Gleim, S., Kasza, Z., Rao, Y., Martel, L., et al. (2008) · Circulation Research · doi:10.1161/circresaha.107.165936 · Cited by 124
Prostaglandin F 2α elevates blood pressure and promotes atherosclerosis
Yu, Y., Lucitt, M. B., Stubbe, J., Cheng, Y., Friis, U. G., Hansen, P., Jensen, B. L., Smyth, E. M., & FitzGerald, G. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811834106 · Cited by 120
COX-2–Derived Prostacyclin Modulates Vascular Remodeling
Rudic, R. D., Brinster, D. R., Cheng, Y., Fries, S., Song, W., Austin, S. C., Coffman, T. M., & FitzGerald, G. A. (2005) · Circulation Research · doi:10.1161/01.res.0000170888.11669.28 · Cited by 116
Taubert, K. A., Antman, E. M., BENNETT, J. S., Daugherty, A., Furberg, C. D., & Roberts, H. R. (2007) · Cited by 113
Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting
Guan, Y., Zhang, Y., Wu, J., Qi, Z., Yang, G., Dou, D., Gao, Y., Chen, L., Zhang, X., Davis, L. S., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29838 · Cited by 109
Wang, T. Y., Xiao, L., Alexander, K. P., Rao, S. V., Kosiborod, M., Rumsfeld, J. S., Spertus, J. A., & Peterson, E. D. (2008) · Circulation · doi:10.1161/circulationaha.108.787143 · Cited by 109
The platelet P2 receptors as molecular targets for old and new antiplatelet drugs
Gachet, C. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.03.009 · Cited by 106
Balancing prostanoid activity in the human vascular system
Flavahan, N. A. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.01.003 · Cited by 104
Sellers, M., & Stallone, J. N. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01318.2007 · Cited by 103
Shehab, N., Sperling, L. S., Kegler, S. R., & Budnitz, D. S. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.407 · Cited by 102
Platelet P2 receptors: old and new targets for antithrombotic drugs
Cattaneo, M. (2007) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.5.1.45 · Cited by 101
Cattaneo, M., & Lecchi, A. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02356.x · Cited by 98
Bailey, J. M., Muza, B., Hla, T., & Salata, K. (1985) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34404-7 · Cited by 97
Kyrle, P. A., Eichler, H. G., Jaeger, U., & Lechner, K. (1987) · Circulation · doi:10.1161/01.cir.75.5.1025 · Cited by 97
Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy
Armstrong, P. C. J., Dhanji, A.-R., Tucker, A., Mitchell, J. A., & Warner, T. D. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03714.x · Cited by 90
Self-citationDeeb, R. S., Upmacis, R. K., Lamon, B. D., Gross, S. S., & Hajjar, D. P. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.092866 · Cited by 87
Expression of Cyclo-oxygenase-2 in Human Atherosclerotic Carotid Arteries
Stemme, V., Swedenborg, J., Claesson, H. E., & Hansson, G. K. (2000) · European Journal of Vascular and Endovascular Surgery · doi:10.1053/ejvs.2000.1145 · Cited by 84
Low-Dose Aspirin, Coxibs, and other NSAIDS: A Clinical Mosaic Emerges
Patrono, C., & Baigent, C. (2009) · Molecular Interventions · doi:10.1124/mi.9.1.8 · Cited by 70
McAdam, B. F., Byrne, D. W., Morrow, J. D., & Oates, J. A. (2005) · Circulation · doi:10.1161/circulationaha.105.542696 · Cited by 69
The Gi-coupled P2Y12 Receptor Regulates Diacylglycerol-mediated Signaling in Human Platelets
Guidetti, G. F., Lova, P., Bernardi, B., Campus, F., Baldanzi, G., Graziani, A., Balduini, C., & Torti, M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801588200 · Cited by 69
Weber, A., Przytulski, B., Schumacher, M., Zimmermann, N., Gams, E., Hohlfeld, T., & Schrör, K. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03423.x · Cited by 55
HAMILTON, L. C., Mitchell, J. A., Tomlinson, A., & Warner, T. D. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.2.245 · Cited by 55
Self-citationGao, X.-R., Adhikari, C. M., Peng, L.-Y., Guo, X., Zhai, Y.-S., He, X., Zhang, L., Lin, J., & Zuo, Z. (2009) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp/61.11.0010 · Cited by 54
COX-2 in play at the AHA and the FDA
FitzGerald, G. A. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.05.007 · Cited by 54
Sample, D., Wargovich, M. J., Fischer, S. M., Inamdar, N., Schwartz, P. E., Wang, X., Do, K.-A., & Sinicrope, F. A. (2002) · PubMed · Cited by 53
Warner, T. D., Vojnovic, I., Giuliano, F., Jiménez, R., Bishop‐Bailey, D., & Mitchell, J. A. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.063875 · Cited by 51
Self-citationGerrard, J. M., Taback, S. P., Singhroy, S., et al. (1989) · Circulation · doi:10.1161/01.cir.79.1.29 · Cited by 51
Armstrong, P. C. J., Dhanji, A.-R., Truss, N. J., Zain, Z. N. M., Tucker, A. T., Mitchell, J. A., & Warner, T. D. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-04-0215 · Cited by 51
Self-citationHinz, B., & Brune, K. (2007) · Springer eBooks · doi:10.1007/978-3-540-33823-9_3 · Cited by 50
Aspirin and Clopidogrel Resistance
Fitzgerald, D. J., & Maree, A. O. (2007) · Hematology · doi:10.1182/asheducation-2007.1.114 · Cited by 49
Cattaneo, M. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03382.x · Cited by 42
Seeking the optimal aspirin dose in acute coronary syndromes
Kong, D. F., Hasselblad, V., Kandzari, D. E., Newby, L. K., & Califf, R. M. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02566-3 · Cited by 39
McGettigan, P., Han, P., Jones, L., Whitaker, D., & Henry, D. A. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03121.x · Cited by 36
Hennekens, C. H., & Borzak, S. L. (2008) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248407312990 · Cited by 36
COX-2-specific inhibitors and the kidney: effect on hypertension and oedema.
Herrera-Acosta, J., Tapia, E., Sánchez-Lozada, L. G., Franco, M., Striker, L. J., Striker, G. E., & Rodríguez, I. B. (2002) · PubMed · Cited by 32
Cited by
Mahaffey, K. W., Wojdyla, D. M., Carroll, K., Becker, R. C., Storey, R. F., Angiolillo, D. J., Held, C., Cannon, C. P., James, S., Pieper, K. S., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.047498 · Cited by 434
Chow, J. H., Khanna, A. K., Kethireddy, S., Yamane, D., Levine, A., Jackson, A. M., McCurdy, M. T., Tabatabai, A., Kumar, G., Park, P., et al. (2021) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000005292 · Cited by 309
Twine, C. P., Kakkos, S. K., Aboyans, V., Baumgartner, I., Behrendt, C.-A., Bellmunt-Montoya, S., Jilma, B., Nordanstig, J., Saratzis, A., Reekers, J. A., et al. (2023) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2023.03.042 · Cited by 197
Chang, M. C., Kwak, S. G., Park, J.-S., & Park, D. (2020) · Scientific Reports · doi:10.1038/s41598-020-71813-1 · Cited by 17
Metadata
- Authors
- Warner, T. D., Nylander, S., & Whatling, C.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2011-09-09
- Volume
- 72
- Issue
- 4
- Pages
- 619-633
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1608454038
- Cited by
- 245
- References
- 119
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.